Nina Bijker

Breast-Conserving Treatment With or Without Radiotherapy in Ductal Carcinoma-In-Situ: Ten-Year Results of European Organisation for Research and Treatment of Cancer Randomized Phase III Trial 10853—A Study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group

Nina Bijker, Philip Meijnen, Johannes L. Peterse et al. · Journal of Clinical Oncology · 2006 · 663 citations

Medicine, Oncology, Radiation Oncology +16

Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853

Jean‐Pierre Julien, Nina Bijker, Ian S. Fentiman et al. · The Lancet · 2000 · 513 citations

Medicine, Oncology, Radiation Oncology +12

Risk Factors for Recurrence and Metastasis After Breast-Conserving Therapy for Ductal Carcinoma-In-Situ: Analysis of European Organization for Research and Treatment of Cancer Trial 10853

Nina Bijker, Johannes L. Peterse, Luc Duchateau et al. · Journal of Clinical Oncology · 2001 · 498 citations

Medicine, Oncology, Surgery +17

Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ – The LORD study

Lotte E. Elshof, Konstantinos Tryfonidis, Leen Slaets et al. · European Journal of Cancer · 2015 · 380 citations · Full text

Medicine, Oncology, Breast Oncology +12

Breast-Conserving Treatment With or Without Radiotherapy in Ductal Carcinoma In Situ: 15-Year Recurrence Rates and Outcome After a Recurrence, From the EORTC 10853 Randomized Phase III Trial

Mila Donker, Saskia Litière, Gustavo Werutsky et al. · Journal of Clinical Oncology · 2013 · 379 citations · Full text

Medicine, Oncology, Surgery +17